

Review Article



The emerging role of MALAT1 lncRNA in diabetic nephropathy: based on the review of the literature and bioinformatic analysis

Shekoofeh Nikooei¹, Erfan Azadifar², Behnam Alipoor^{2*}¹ Student Research Committee, Yasuj University of Medical Sciences, Yasuj, Iran.² Department of Laboratory Sciences, Faculty of Paramedicine, Yasuj University of Medical Sciences, Yasuj, Iran.**Article info:****Received:** 1 September 2023**Revised:** 25 September 2023**Accepted:** 7 October 2023*** Corresponding Author:**

Behnam Alipoor,
Department of Laboratory Sciences,
Faculty of Paramedicine, Yasuj
University of Medical Sciences, Yasuj,
Iran.
Email: behnam.alipoor@yums.ac.ir

ABSTRACT

Previous studies have found that the metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) exerts its biological effects on the progression of diabetic nephropathy by sponging microRNAs and affecting the gene transcription of downstream molecules. In this study, the primary emphasis is placed on the functions that MALAT1 plays in relation to the pathophysiology of diabetic nephropathy as well as the processes that underlie these roles. In addition, the usage of this long noncoding RNA as a possible biomarker or therapeutic target for diabetic nephropathy will be discussed.

Keywords: long Noncoding RNA, MALAT1, MicroRNA, Diabetic Nephropathy**Abbreviations:** AMPK: AMP-activated protein kinase; circRNAs: circular RNAs; ceRNA: competing endogenous RNAs; DKD: diabetic kidney disease; DN: Diabetic nephropathy; DM: diabetes mellitus; EMT: epidermal to melanin transition; ERSD: stage renal disease; FoxO: forkhead box O; GFR: glomerular filtration rate; HIF-1: hypoxia-inducible factor 1; NLRP3: NOD-like receptor protein 3; MALAT1: metastasis-associated lung adenocarcinoma transcript 1; mTOR: mammalian target of rapamycin; ncRNA: noncoding RNA; lncRNAs; long noncoding RNAs; PI3K: phosphoinositide 3-kinase; Ras: rat sarcoma viral oncogene; TF: transcription factor; T2D; type 2 diabetesUse your device to scan
and read the article online**Citation:** Nikooei Sh, Azadifar E, Alipoor B. The emerging role of MALAT1 lncRNA in diabetic nephropathy: based on the review of the literature and bioinformatic analysis. *Acta Biochimica Iranica*. 2023;1(3):105-111. <https://doi.org/10.18502/abi.v1i3.14545>**Introduction**

Dabetic nephropathy (DN), also known as diabetic kidney disease (DKD), is regarded as one of the most serious microvascular consequences of diabetes mellitus (DM) (1). DN is the major cause of end-stage renal disease (ESRD) worldwide, which is related to higher morbidity and mortality in patients with diabetes (2). Patients with diabetes have a

thirty to forty percent chance of developing DN (3). The overall prevalence of nephropathy in individuals with type 2 diabetes (T2D) in Iran was found to be 30.6%, according to a meta-analysis that included 18 papers and 6190 people ranging in age from 20 to 83 years (4). The increased excretion of albumin, hyperglycemia, hypertension, dyslipidemia, obesity, and smoking are some of the key risk factors that contribute to the development and progression of DN (5, 6).

The diagnosis of DN is made in the laboratory based



on the presence of albuminuria over a prolonged period of time and a gradual decline in glomerular filtration rate (GFR) (7). However, albuminuria has a number of drawbacks, such as a high degree of variability and a low degree of sensitivity, and the level of albuminuria sometimes cannot correctly reflect the particular situation of DN (8). In addition, the fall of GFR without albuminuria, also known as nonproteinuric diabetic kidney disease, has been increasingly identified, particularly in subjects with T2D (9, 10). As a result, a growing number of innovative biomarkers have surfaced with the purpose of identifying individuals who are at risk of developing DKD as well as early DKD in the hope of preventing the occurrence of ESRD (11).

In recent years, there has been an uptick in the amount of evidence suggesting that noncoding RNA (ncRNA), in particular long noncoding RNAs (lncRNAs), play an important part in the development and progression of DN (12-16). In addition, a large number of studies have shown that cell-free ncRNAs have been dysregulated in the serum, plasma, urine, and peripheral blood samples of patients with T2D (17-20). The metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), also termed nuclear enriched abundant transcript 2 (NEAT2), is one of the ncRNAs in human disease that has received the most attention from researchers, especially in diabetes and diabetic-related complications (21, 22). In this study, the primary emphasis is placed on the functions that MALAT1 plays in relation to the pathophysiology of DN as well as the processes that underlie these roles. In addition, the discussion will be about the usage of this lncRNA as a possible biomarker or therapeutic target for DN.

Methods

In this narrative review, a systematic literature review was performed using PubMed, Google Scholar, and Web of Science for English up to 4 June 2023, using the terms “DN”, “DKD”, “diabetes”, “lncRNA”, and “MALAT1”. To predict MALAT1-microRNA (miRNA) interactions, experimentally validated miRNA targets of MALAT-1 lncRNA were extracted from the NPInter.V4 database (23). Subsequently, a list of experimentally validated mRNA targets of miRNAs related to MALAT-1 was obtained from the miRTarBase database (24). The KEGG pathway enrichment analysis was carried out using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) and miEAA 2.0 databases to explore functional annotation and pathway enrichment of the extracted target mRNAs (25, 26).

Results and Discussion

LncRNA and miRNA interactions: miRNA Sponge

ncRNA refers to the portion of an RNA molecule that does not get translated into a protein (27). There

are various subclasses of ncRNA, including miRNA, circular RNAs (circRNAs), pseudogenes, tsRNAs, and piRNAs (28). The association of ncRNA with a variety of disorders, including cancer, inflammatory diseases, and metabolic diseases, has been the subject of a significant number of research studies (29, 30). miRNA is a type of single-stranded (ss) RNA transcript that has the function of post-transcriptional control and RNA silencing (31). RNA polymerase II and RNA Pol III (for some of them) are the enzymes responsible for the transcription of key miRNAs (32). The process of transcription results in the production of pri-miRNA molecules, which have changes similar to those found in mRNA, such as 5' capping and 3' polyadenylation, and have a hairpin structure that covers the mature miRNA sequence (29). miRNAs interact with short complementary sequences in the 3' untranslated regions and govern cell cycle progression, apoptosis, and cellular development (33).

lncRNAs are single-stranded (ss) RNA with a length of 200 nucleotides. These RNAs are unable to encode proteins (34). Through the control of genomic expression, epigenetic alteration, and post-transcriptional regulation in cis or trans, lncRNAs play a significant role in a variety of physiological and pathological cellular functions (35). Additional important roles played by lncRNAs include genetic imprinting, genomic rearrangement, regulation of the cell cycle, and splicing (36, 37). The interaction between microRNAs and long noncoding RNAs, known as miRNA sponge or competing endogenous RNAs (ceRNA), can diminish the inhibitory effects of miRNAs on mRNAs or sponge them (38). Indeed, lncRNAs have the potential to behave as a sponge, soaking up a greater proportion of the miRNAs that are available to the target mRNA, thereby preventing the target gene repression (39) (**Figure 1**).

The prediction of MALAT1-miRNA interactions in DM

The MALAT1 gene is located within human chromosome 11q13 and was initially discovered in a screen for transcripts associated with metastasis and patient survival in non-small cell lung cancer (40, 41). The major mechanisms of post-transcriptional regulation of MALAT1 include alternative splicing, promoting trimethylation of histone H3 at lysine 27, and facilitating transcription factor (TF) binding to the promoter of target genes and ceRNAs (42, 43).

The bioinformatics analysis revealed that ninety-two experimentally validated miRNA targets for MALAT-1 were identified by the NPInter database. The enrichments of the miRNAs in KEGG pathway categories were performed using miEAA 2.0 databases. The significant KEGG pathway categories and correlated miRNAs were presented in the heatmap generated in DIANA-miRPath. Moreover, enrichment analysis revealed that the 32 miRNA targets of MALAT-1 were enriched in diabetes-related pathways including hypoxia-inducible factor




Figure 1. Schematic overview of the interaction between lncRNA and miRNAs. miRNA sponge or competing endogenous RNAs (ceRNA) could diminish the inhibitory effects of miRNAs on mRNAs or sponge them.

Table 1: KEGG pathways enrichment analysis for genes regulated by MALAT1-miRNAs axis

Subcategory	Enrichment	P-value	P-adjusted	Observed	genes
HIF-1 signaling pathway	depleted	4.57e-6	1.33e-4	9	29
FoxO signaling pathway	depleted	3.85e-5	4.62e-4	10	37
PI3K-Akt signaling pathway	depleted	3.04e-5	4.62e-4	12	69
MAPK signaling pathway	depleted	5.84e-5	6.42e-4	7	54
Rap1 signaling pathway	depleted	2.36e-4	0.001353	7	38
Ras signaling pathway	depleted	2.36e-4	0.001353	7	40
mTOR signaling pathway	depleted	1.77e-4	0.001353	4	22
TGF-beta signaling pathway	depleted	8.43e-4	0.0042801	6	23
Wnt signaling pathway	depleted	0.0013139	0.005527	3	21
Toll-like receptor signaling pathway	depleted	0.0017519	0.0068014	3	24
Jak-STAT signaling pathway	depleted	0.0096295	0.0249234	6	26

1 (HIF-1) signaling pathway, forkhead box O (FoxO) signaling pathway, phosphoinositide 3-kinase (PI3K)-Akt signaling pathway, rat sarcoma viral oncogene (Ras) signaling pathway and mammalian target of rapamycin (mTOR) signaling pathway (**Table 1**).

The role of MALAT1-miRNA interactions in DN

Previous studies have found that MALAT1 exerts its biological effects on the progression of DN by sponging miRNAs, interacting with miRNAs, and affecting the gene transcription of downstream molecules (Figure 2). The focus here is on the potential function of MALAT1

as a miRNA sponge in DN.

MALAT1 facilitates high glucose-induced endothelial-to-mesenchymal transition and renal fibrosis

Renal fibrosis is an important stage in the progression of DN into ESRD (44). This pathological event takes place as a result of an abnormally high level of extracellular matrix being deposited in the kidney tissue as a result of hyperglycemia, inflammation, and oxidative stress (45, 46). In recent years, it has been reported that ncRNA is involved in both epithelial-to-mesenchymal transition




Figure 2. Schematic representation of MALAT1 function in DN. Sponging effect of MALAT1 on the miRNAs could induce endothelial-to-mesenchymal transition and renal fibrosis, pyroptosis and tubular impairment in breast DN.

and the damage of tubular cells (47). MALAT1 is one of the ncRNAs whose role in endothelial-to-mesenchymal transition and renal fibrosis has been explored. It has been demonstrated that MALAT1 is capable of acting as a sponge RNA for miR-145, which allows it to control the expression of the target gene ZEB2 and, as a result, induce epidermal to melanin transition (EMT) as well as fibrosis (48). Upregulation of MALAT1 in response to high glucose treatment has been shown to induce EMT in HK-2 cells by activating the Wnt/-catenin pathway (49). Huang et al. demonstrated that MALAT1 expression levels are increased in renal tissues of diabetic rats and high glucose-treated cells. This was associated with an increase in protein levels of collagen I and IV, fibronectin, and laminin in HK-2 cells. They also found that MALAT1 overexpression caused the level of miR-2355-3p to decrease, which led to the induction of cell damage, renal fibrosis, and kidney tissue destruction via the miR-2355-3p/IL6ST/STAT3 signaling pathway (50). Furthermore, it has been shown that the expression levels of MALAT1 were upregulated in renal fibrotic tissues in diabetic patients and this lncRNA could worsen renal fibrogenesis in obstructive nephropathy through the miR-145/FAK pathway (51).

The interplay between lncRNA-MALAT1 and pyroptosis

It has been suggested that pyroptosis and further inflammatory response play a critical role in the DN pathogenesis (52). Pyroptosis is an inflammatory programmed cell death that is mediated by the activation of caspase-1 following the formation of the NOD-like receptor protein 3 (NLRP3) inflammasome complex (53). A number of studies have reported the influence of lncRNAs/miRNAs interaction in pyroptosis. In this regard, it has been reported that downregulation of MALAT1 could induce cell pyroptosis by inhibiting miR-30c targeting for NLRP3 in the high glucose-treated HK-2 cells (51). Moreover, Li et al. reported that lncRNA

MALAT1 could moderate renal tubular epithelial pyroptosis by modulating the miR-23c-ELAVL1 axis in high-glucose-treated HK-2 cells (54). The findings of a recent study showed that knocking down of the MALAT1 protects MPC-5, a mouse podocyte cell line, against pyroptosis and oxidative stress caused by HG. This protection was achieved by the modulation of miR-200c and the expression of its target genes (55).

MALAT1 mediates tubular impairment induced by hyperglycemia and inflammation

One of the most important factors that contributes to the development of DN is tubular impairment, which can be caused by hyperglycemia (9). MALAT1 could activate the AMP-activated protein kinase (AMPK)/mTOR signaling by interacting with LIN28A and Nox4/AMPK/mTOR signaling axis, thereby worsening high glucose-induced renal tubular injury (56). It has also been suggested that downregulation of MALAT1 attenuates HK-2 cell viability inhibition, apoptosis, and inflammation induced by hyperglycemia by targeting miR-15b-5p (57). Interestingly, XU et al. revealed that paclitaxel could protect against LPS-induced acute kidney injury via the modulation of MALAT1/miR-370-3p/HMGB1 axis and the expression of TNF- α , IL-6 and IL-1 β (58). A recent study investigated the involvement of MALAT1 lncRNA in the progression of cellular inflammation and renal tubular epithelial cell injury. The results revealed that the downregulation of MALAT1 may be able to reduce the severity of acute kidney injury by acting as a mediator of the miR-204/APOL1 pathway (59).

MALAT1 as a therapeutic target in DN

The evidence indicates that MALAT1 could act as a potential therapeutic target for the diagnosis and treatment of diabetes-related complications including DN (60). QiHuangYiShen, a traditional Chinese herbal

medicine formula, attenuates epithelial-mesenchymal transition in the kidney of diabetic nephropathy rats by the downregulation of MALAT1 lncRNA (61). Zuo et al. suggested that Atorvastatin exerts its protective effect on the kidney through the regulation of MALAT1 expression and reduction of oxidative stress. Indeed, they reported that Atorvastatin protects podocyte cells via the MALAT1/miR-200c/NRF2 signal pathway from pyroptosis and oxidative stress induced by high glucose treatment (55). Resveratrol (3,4',5-trihydroxystilbene) is a polyphenol anti-toxin that can prevent a wide range of human diseases, including diabetes (62-64). Resveratrol reduced the expression levels of MALAT1 and thereby alleviated sepsis-induced acute kidney injury in cecal ligation and puncture (CLP)-induced septic model rats by deactivating the lncRNA MALAT1/MiR-205 axis (65).

Diagnostic role of MALAT1 as in DN

Promising evidence has revealed that lncRNAs could serve as potential biomarkers for early diagnosis of diabetes and its complications (17, 37). In this regard, it has been demonstrated that MALAT1 is significantly upregulated in DN tissues compared with normal (57). Fawzy et al. reported that serum levels of MALAT1 were elevated in the ESRD group compared to diabetics without ESRD. They also revealed that MALAT1 expression levels were correlated with higher levels of total triglyceride (66). In line with this finding, it has been shown that MALAT1 expression is increased in the micro-albuminuria diabetic group compared with the diabetic normoalbuminuria group and could act as a potential biomarker for early detection of DN (67). Furthermore, MALAT1 serum level has recently been recognized as a potential biomarker with high sensitivity and specificity to differentiate acute kidney injury patients from control subjects (59). It has also been reported that serum levels of MALAT1 had a direct correlation with urinary MALAT1 and miRNA-124 serum levels and negatively with miRNA 29a serum levels and eGFR (68). Zhou et al. revealed that the MALAT1 expression profile in peripheral blood mononuclear cells was increased in diabetic kidney disease groups compared to control. They also reported that MALAT1 expression levels were correlated with ACR, urine β -microglobulin, urine α 1-microglobulin, and creatinine (69). Recent studies have shown that the expression levels of MALAT1 are increased in the urine samples of type 1 diabetes patients with diabetic kidney disease (21).

Conclusion

Increasing evidence has demonstrated that lncRNA, especially MALAT1, plays a critical role in the pathogenesis and progression of DN. Accordingly, this review explored and clarified the sophisticated research

and progress with the possible roles of MALAT1 in DN. MALAT1 exerts its effect through interaction with miRNAs and modulating their effects on important signaling pathways involved in the development and progression of DN. Furthermore, based on the literature discussed above, pharmacological and diagnostic targeting of MALAT1 may serve as a potential alternative strategy for the diagnosis and treatment of DN.

Conflict of Interest

Author has no conflict of interest.

References

1. Piwkowska A, Zdrojewski Ł, Heleniak Z, Dębska-Ślizień A. Novel Markers in Diabetic Kidney Disease-Current State and Perspectives. *Diagnostics (Basel)*. 2022;12(5). <https://doi.org/10.3390/diagnostics12051205>
2. Zoecali C, Mallamaci F. Nonproteinuric progressive diabetic kidney disease. *Curr Opin Nephrol Hypertens*. 2019;28(3):227-232. <https://doi.org/10.1097/MNH.0000000000000489>
3. Umanath K, Lewis JB. Update on Diabetic Nephropathy: Core Curriculum 2018. *Am J Kidney Dis*. 2018;71(6):884-895. <https://doi.org/10.1053/j.ajkd.2017.10.026>
4. Rabieenia E, Jalali R, Mohammadi M. Prevalence of nephropathy in patients with type 2 diabetes in Iran: A systematic review and meta-analysis based on geographic information system (GIS). *Diabetes Metab Syndr*. 2020;14(5):1543-1550. <https://doi.org/10.1016/j.dsx.2020.08.007>
5. Nagib AM, Matter YE, Gheith OA, Refaie AF, Othman NF, Al-Otaibi T. Diabetic Nephropathy Following Posttransplant Diabetes Mellitus. *Exp Clin Transplant*. 2019;17(2):138-146. <https://doi.org/10.6002/ect.2018.0157>
6. Mazloom H, Alizadeh S, Pasalar P, Esfahani EN, Meshkani R. Downregulated microRNA-155 expression in peripheral blood mononuclear cells of type 2 diabetic patients is not correlated with increased inflammatory cytokine production. *Cytokine*. 2015;76(2):403-408. <https://doi.org/10.1016/j.cyto.2015.07.007>
7. Satirapoj B. Review on pathophysiology and treatment of diabetic kidney disease. *J Med Assoc Thai*. 2010;93 Suppl 6:S228-41.
8. Gu YY, Lu FH, Huang XR, Zhang L, Mao W, Yu XQ, et al. Non-Coding RNAs as Biomarkers and Therapeutic Targets for Diabetic Kidney Disease. *Front Pharmacol*. 2020;11:583528. <https://doi.org/10.3389/fphar.2020.583528>
9. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. *Jama*. 2003;289(24):3273-7. <https://doi.org/10.1001/jama.289.24.3273>
10. Chen Y, Lee K, Ni Z, He JC. Diabetic Kidney Disease: Challenges, Advances, and Opportunities. *Kidney Dis (Basel)*. 2020;6(4):215-225. <https://doi.org/10.1159/000506634>
11. Cao Q, Chen XM, Huang C, Pollock CA. MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: An update. *FASEB Bioadv*. 2019;1(6):375-388. <https://doi.org/10.1096/fba.2018-00064>
12. Chen K, Yu B, Liao J. LncRNA SOX2OT alleviates mesangial cell proliferation and fibrosis in diabetic nephropathy via Akt/mTOR-mediated autophagy. *Mol Med*. 2021;27(1):71. <https://doi.org/10.1186/s10020-021-00310-6>

13. Ge Y, Wang J, Wu D, Zhou Y, Qiu S, Chen J, et al. lncRNA NR_038323 Suppresses Renal Fibrosis in Diabetic Nephropathy by Targeting the miR-324-3p/DUSP1 Axis. *Mol Ther Nucleic Acids*. 2019;17:741-753. <https://doi.org/10.1016/j.omtn.2019.07.007>
14. Afrookhteh A, Emamgholipour S, Alipoor B, Moradi N, Meshkani R, Nasli-Esfahani E, et al. The Circulating Levels of Complement-C1q/TNF-Related Protein 13 (CTRP13) in Patients with Type 2 Diabetes and its Association with Insulin Resistance. *Clin Lab*. 2017;63(2):327-333. <https://doi.org/10.7754/Clin.Lab.2016.160609>
15. Samavarchi Tehrani S, Goodarzi G, Panahi G, Maniati M, Meshkani R. Multiple novel functions of circular RNAs in diabetes mellitus. *Arch Physiol Biochem*. 2021;1-30. <https://doi.org/10.1080/13813455.2021.1933047>
16. Tehrani SS, Ebrahimi R, Al-e-Ahmad A, Panahi G, Meshkani R, Younesi S, et al. Competing endogenous RNAs (CeRNAs): novel network in neurological disorders. *Curr Med Chem*. 2021;28(29):5983-6010. <https://doi.org/10.2174/0929867328666201217141837>
17. Parvar SN, Mirzaei A, Zare A, Doustimotlagh AH, Nikooei S, Arya A, et al. Effect of metformin on the long non-coding RNA expression levels in type 2 diabetes: an in vitro and clinical trial study. *Pharmacol Rep*. 2023;75(1):189-198. <https://doi.org/10.1007/s43440-022-00427-3>
18. Ghorbani S, Mahdavi R, Alipoor B, Panahi G, Nasli Esfahani E, Razi F, et al. Decreased serum microRNA-21 level is associated with obesity in healthy and type 2 diabetic subjects. *Arch Physiol Biochem*. 2018;124(4):300-305. <https://doi.org/10.1080/13813455.2017.1396349>
19. Giannella A, Castelblanco E, Zambon CF, Basso D, Hernandez M, Ortega E, et al. Circulating Small Noncoding RNA Profiling as a Potential Biomarker of Atherosclerotic Plaque Composition in Type 1 Diabetes. *Diabetes Care*. 2023;46(3):551-560. <https://doi.org/10.2337/dc22-1441>
20. Xu YX, Pu SD, Li X, Yu ZW, Zhang YT, Tong XW, et al. Exosomal ncRNAs: Novel therapeutic target and biomarker for diabetic complications. *Pharmacol Res*. 2022;178:106135. <https://doi.org/10.1016/j.phrs.2022.106135>
21. Dieter C, Lemos NE, Girardi E, Ramos DT, Corrêa NRF, Canani LH, et al. The lncRNA MALAT1 is upregulated in urine of type 1 diabetes mellitus patients with diabetic kidney disease. *Genet Mol Biol*. 2023;46(2):e20220291. <https://doi.org/10.1590/1678-4685-gmb-2022-0291>
22. Panahi G, Pasalar P, Zare M, Rizzuto R, Meshkani R. MCU-knockdown attenuates high glucose-induced inflammation through regulating MAPKs/NF-κB pathways and ROS production in HepG2 cells. *PLoS One*. 2018;13(4):e0196580. <https://doi.org/10.1371/journal.pone.0196580>
23. Teng X, Chen X, Xue H, Tang Y, Zhang P, Kang Q, et al. NPInter v4.0: an integrated database of ncRNA interactions. *Nucleic Acids Res*. 2020;48(D1):D160-D165. <https://doi.org/10.1093/nar/gkz969>
24. Huang HY, Lin YC, Li J, Huang KY, Shrestha S, Hong HC, et al. miRTarBase 2020: updates to the experimentally validated microRNA-target interaction database. *Nucleic Acids Res*. 2020;48(D1):D148-D154. <https://doi.org/10.1093/nar/gkz896>
25. Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). *Nucleic Acids Res*. 2022;50(W1):W216-W221. <https://doi.org/10.1093/nar/gkac194>
26. Kern F, Fehlmann T, Solomon J, Schwed L, Grammes N, Backes C, et al. miEAA 2.0: integrating multi-species microRNA enrichment analysis and workflow management systems. *Nucleic Acids Res*. 2020;48(W1):W521-W528. <https://doi.org/10.1093/nar/gkaa309>
27. Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. *Nat Rev Cancer*. 2018;18(1):5-18. <https://doi.org/10.1038/nrc.2017.99>
28. Slack FJ, Chinnaiyan AM. The Role of Non-coding RNAs in Oncology. *Cell*. 2019;179(5):1033-1055. <https://doi.org/10.1016/j.cell.2019.10.017>
29. Beermann J, Piccoli MT, Viereck J, Thum T. Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. *Physiol Rev*. 2016;96(4):1297-1325. <https://doi.org/10.1152/physrev.00041.2015>
30. Esteller M. Non-coding RNAs in human disease. *Nat Rev Genet*. 2011;12(12):861-874. <https://doi.org/10.1038/nrg3074>
31. Simpson K, Wonnacott A, Fraser DJ, Bowen T. MicroRNAs in Diabetic Nephropathy: From Biomarkers to Therapy. *Curr Diab Rep*. 2016;16(3):35. <https://doi.org/10.1007/s11892-016-0724-8>
32. Hombach S, Kretz M. Non-coding RNAs: Classification, Biology and Functioning. *Adv Exp Med Biol*. 2016;937:3-17. https://doi.org/10.1007/978-3-319-42059-2_1
33. Toden S, Zumwalt TJ, Goel A. Non-coding RNAs and potential therapeutic targeting in cancer. *Biochim Biophys Acta Rev Cancer*. 2021;1875(1):188491. <https://doi.org/10.1016/j.bbcan.2020.188491>
34. Ren H, Wang Q. Non-Coding RNA and Diabetic Kidney Disease. *DNA Cell Biol*. 2021;40(4):553-567. <https://doi.org/10.1089/dna.2020.5973>
35. Lin W, Zhou Q, Wang CQ, Zhu L, Bi C, Zhang S, et al. LncRNAs regulate metabolism in cancer. *Int J Biol Sci*. 2020;16(7):1194-1206. <https://doi.org/10.7150/ijbs.40769>
36. Zhu J, Fu H, Wu Y, Zheng X. Function of lncRNAs and approaches to lncRNA-protein interactions. *Sci China Life Sci*. 2013;56(10):876-885. <https://doi.org/10.1007/s11427-013-4553-6>
37. Alipoor B, Nikouei S, Rezaeinejad F, Malakooti-Dehkordi SN, Sabati Z, Ghasemi H. Long non-coding RNAs in metabolic disorders: pathogenetic relevance and potential biomarkers and therapeutic targets. *J Endocrinol Invest*. 2021;44(10):2015-2041. <https://doi.org/10.1007/s40618-021-01559-8>
38. Venkatesh J, Wasson MD, Brown JM, Fernando W, Marcato P. LncRNA-miRNA axes in breast cancer: Novel points of interaction for strategic attack. *Cancer Lett*. 2021;509:81-88. <https://doi.org/10.1016/j.canlet.2021.04.002>
39. Olgun G, Sahin O, Tastan O. Discovering lncRNA mediated sponge interactions in breast cancer molecular subtypes. *BMC Genomics*. 2018;19(1):650. <https://doi.org/10.1186/s12864-018-5006-1>
40. Wilusz JE. Long noncoding RNAs: Re-writing dogmas of RNA processing and stability. *Biochim Biophys Acta*. 2016;1859(1):128-138. <https://doi.org/10.1016/j.bbagr.2015.06.003>
41. Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. *Oncogene*. 2003;22(39):8031-41. <https://doi.org/10.1038/sj.onc.1206928>
42. Shi X, Sun M, Wu Y, Yao Y, Liu H, Wu G, et al. Post-transcriptional regulation of long noncoding RNAs in cancer. *Tumour Biol*. 2015;36(2):503-13. <https://doi.org/10.1007/s13277-015-3106-y>
43. Amodio N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P, et al. MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches. *J Hematol Oncol*.

- 2018;11(1):63. <https://doi.org/10.1186/s13045-018-0606-4>
44. Valencia WM, Florez H. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. *BMJ*. 2017;356:i6505. <https://doi.org/10.1136/bmj.i6505>
 45. Chen Y, Zou H, Lu H, Xiang H, Chen S. Research progress of endothelial-mesenchymal transition in diabetic kidney disease. *J Cell Mol Med*. 2022;26(12):3313-3322. <https://doi.org/10.1111/jcmm.17356>
 46. Shiri H, Sattari M, Hemmati S, Seyyedehbrahimi S, Panahi G. Evaluation of Antioxidant Potential and Free Radical Scavenging Activity of Methanol Extract from *Scrophularia striata*. *Acta Biochim Iran*. 2023;1(2):71-77. <https://doi.org/10.18502/abi.v1i2.14103>
 47. Shi S, Song L, Yu H, Feng S, He J, Liu Y, et al. Knockdown of lncRNA-H19 Ameliorates Kidney Fibrosis in Diabetic Mice by Suppressing miR-29a-Mediated EndMT. *Front Pharmacol*. 2020;11:586895. <https://doi.org/10.3389/fphar.2020.586895>
 48. Liu B, Qiang L, Wang GD, Duan Q, Liu J. lncRNA MALAT1 facilitates high glucose induced endothelial to mesenchymal transition and fibrosis via targeting miR-145/ZEB2 axis. *Eur Rev Med Pharmacol Sci*. 2019;23(8):3478-3486.
 49. Zhang J, Jiang T, Liang X, Shu S, Xiang X, Zhang W, et al. lncRNA MALAT1 mediated high glucose-induced HK-2 cell epithelial-to-mesenchymal transition and injury. *J Physiol Biochem*. 2019;75(4):443-452. <https://doi.org/10.1007/s13105-019-00688-2>
 50. Huang H, Zhang G, Ge Z. lncRNA MALAT1 Promotes Renal Fibrosis in Diabetic Nephropathy by Targeting the miR-2355-3p/IL6ST Axis. *Front Pharmacol*. 2021;12:647650. <https://doi.org/10.3389/fphar.2021.647650>
 51. Liu C, Zhuo H, Ye MY, Huang GX, Fan M, Huang XZ. lncRNA MALAT1 promoted high glucose-induced pyroptosis of renal tubular epithelial cell by sponging miR-30c targeting for NLRP3. *Kaohsiung J Med Sci*. 2020;36(9):682-691. <https://doi.org/10.1002/kjm2.12226>
 52. Zhan JF, Huang HW, Huang C, Hu LL, Xu WW. Long Non-Coding RNA NEAT1 Regulates Pyroptosis in Diabetic Nephropathy via Mediating the miR-34c/NLRP3 Axis. *Kidney Blood Press Res*. 2020;45(4):589-602. <https://doi.org/10.1159/000508372>
 53. Lu L, Zhang Y, Tan X, Merkhery Y, Leonov S, Zhu L, et al. Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer. *Cell Death Discov*. 2022;8(1):338. <https://doi.org/10.1038/s41420-022-01101-6>
 54. Li X, Zeng L, Cao C, Lu C, Lian W, Han J, et al. Long noncoding RNA MALAT1 regulates renal tubular epithelial pyroptosis by modulated miR-23c targeting of ELAVL1 in diabetic nephropathy. *Exp Cell Res*. 2017;350(2):327-335. <https://doi.org/10.1016/j.yexcr.2016.12.006>
 55. Zuo Y, Chen L, He X, Ye Z, Li L, Liu Z, et al. Atorvastatin Regulates MALAT1/miR-200c/NRF2 Activity to Protect Against Podocyte Pyroptosis Induced by High Glucose. *Diabetes Metab Syndr Obes*. 2021;14:1631-1645. <https://doi.org/10.2147/DMSO.S298950>
 56. Song P, Chen Y, Liu Z, Liu H, Xiao L, Sun L, et al. lncRNA MALAT1 Aggravates Renal Tubular Injury via Activating LIN28A and the Nox4/AMPK/mTOR Signaling Axis in Diabetic Nephropathy. *Front Endocrinol (Lausanne)*. 2022;13:895360. <https://doi.org/10.3389/fendo.2022.895360>
 57. Yang Z, Song D, Wang Y, Tang L. lncRNA MALAT1 Promotes Diabetic Nephropathy Progression via miR-15b-5p/TLR4 Signaling Axis. *J Immunol Res*. 2022;2022:8098001. <https://doi.org/10.1155/2022/8098001>
 58. Xu L, Hu G, Xing P, Zhou M, Wang D. Paclitaxel alleviates the sepsis-induced acute kidney injury via lnc-MALAT1/miR-370-3p/HMGB1 axis. *Life Sci*. 2020;262:118505. <https://doi.org/10.1016/j.lfs.2020.118505>
 59. Lu HY, Wang GY, Zhao JW, Jiang HT. Knockdown of lncRNA MALAT1 ameliorates acute kidney injury by mediating the miR-204/APOL1 pathway. *J Clin Lab Anal*. 2021;35(8):e23881. <https://doi.org/10.1002/jcla.23881>
 60. Abdulle LE, Hao JL, Pant OP, Liu XF, Zhou DD, Gao Y, et al. MALAT1 as a Diagnostic and Therapeutic Target in Diabetes-Related Complications: A Promising Long-Noncoding RNA. *Int J Med Sci*. 2019;16(4):548-555. <https://doi.org/10.7150/ijms.30097>
 61. Yuan LS, Du H, Ren QY, Yang RL, Liu SW, Liu SY, et al. QiHuangYiShen Granules Modulate the Expression of lncRNA MALAT1 and Attenuate Epithelial-Mesenchymal Transition in Kidney of Diabetic Nephropathy Rats. *Evid Based Complement Alternat Med*. 2023;2023:3357281. <https://doi.org/10.1155/2023/3357281>
 62. Su M, Zhao W, Xu S, Weng J. Resveratrol in Treating Diabetes and Its Cardiovascular Complications: A Review of Its Mechanisms of Action. *Antioxidants (Basel)*. 2022;11(6). <https://doi.org/10.3390/antiox11061085>
 63. Sattar Gorgani-Firuzjaee R, Meshkani R. Resveratrol reduces high glucose-induced de-novo lipogenesis through mTOR mediated induction of autophagy in HepG2 cells. *Acta Biochim Iran*. 2023;1(1):32-39. <https://doi.org/10.18502/abi.v1i1.14063>
 64. Ghahremani H, Bolandnazar K, Emamgholipor S, Hosseini H, Meshkani R. Resveratrol as a Potential Protective Compound Against Metabolic Inflammation. *Acta Biochim Iran*. 2023;1(2):50-64. <https://doi.org/10.18502/abi.v1i2.14101>
 65. Wang B, Wang Y, Xu K, Zeng Z, Xu Z, Yue D, et al. Resveratrol alleviates sepsis-induced acute kidney injury by deactivating the lncRNA MALAT1/MiR-205 axis. *Cent Eur J Immunol*. 2021;46(3):295-304. <https://doi.org/10.5114/ceji.2021.109195>
 66. Fawzy MS, Abu AlSel BT, AlAgeeli E, Al-Qahtani SA, Abdel-Daim MM, Toraih EA. Long non-coding RNA MALAT1 and microRNA-499a expression profiles in diabetic ESRD patients undergoing dialysis: a preliminary cross-sectional analysis. *Arch Physiol Biochem*. 2020;126(2):172-182. <https://doi.org/10.1080/13813455.2018.1499119>
 67. Shoeib HM, Keshk WA, Al-Ghazaly GM, Wagih AA, El-Dardiry SA. Interplay between long non-coding RNA MALAT1 and pyroptosis in diabetic nephropathy patients. *Gene*. 2023;851:146978. <https://doi.org/10.1016/j.gene.2022.146978>
 68. Petrica L, Hogeia E, Gadalean F, Vlad A, Vlad M, Dumitrascu V, et al. Long noncoding RNAs may impact podocytes and proximal tubule function through modulating miRNAs expression in Early Diabetic Kidney Disease of Type 2 Diabetes Mellitus patients. *Int J Med Sci*. 2021;18(10):2093-2101. <https://doi.org/10.7150/ijms.56551>
 69. Zhou LJ, Yang DW, Ou LN, Guo XR, Wu BL. Circulating Expression Level of lncRNA Malat1 in Diabetic Kidney Disease Patients and Its Clinical Significance. *J Diabetes Res*. 2020;2020:4729019. <https://doi.org/10.1155/2020/4729019>